Cyclo Therapeutics will participate in the 2021 virtual conference on cyclodextrin organized by CycloLab

Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of Medical Affairs, will participate in a moderated panel discussion with academics and industry experts on October 11, 2021 at 4:30 p.m. (CET) / 10:30 a.m. (EST)

GAINESVILLE, Florida, October 06, 2021– (COMMERCIAL THREAD) –Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to the development of life-changing drugs through science and innovation for patients and families living with diseases, today announced that it will participate in the Virtual Conference on Cyclodextrin 2021 hosted by CycloLab, “Cyclodextrins as active ingredients in the 21st century “, will take place on October 11, 2021.

The event will focus on the use of cyclodextrins as active ingredients from both a therapeutic / industrial and chemical point of view. As part of the event, Sharon H. Hrynkow, PhD, Chief Scientific Officer, Senior Vice President of Medical Affairs of Cyclo Therapeutics will participate in an interactive and moderated panel discussion with several key opinion leaders in the field and address the issues of the participants. The roundtable will begin at 4:30 p.m. (CET) / 10:30 a.m. (EST).

Trappsol® Cyclo â„¢ is Cyclo Therapeutics’ proprietary formulation of hydroxypropyl beta cyclodextrin and, in numerous clinical studies, has shown encouraging results to effectively manage cholesterol transport. Taking the place of the defective NPC1 protein, Trappsol® Cyclo â„¢, with its cyclic structure, facilitates the transport of accumulated cholesterol out of cell lysosomes so that it can be further processed and excreted out of cells.

Trappsol® Cyclo â„¢ is currently being evaluated in a global pivotal phase 3 trial, “TransportNPC”, for the potential treatment of Niemann-Pick disease type C1 (NPC), a rare, fatal genetic disorder. and scalable. By the end of 2021, Cyclo Therapeutics will submit an IND to the FDA for a Phase 2 trial with Trappsol® Cyclo â„¢ in Alzheimer’s disease, an irreversible and progressive neurological disorder, in which cholesterol is also involved as a risk factor.

For more information and to register for the event, please visit the conference website here.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the development of life-changing drugs through science and innovation for patients and families with disease. The company’s Trappsol® Cyclo â„¢, a drug designated orphan drug in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick disease type C, a rare and fatal genetic disorder ( NCT02939547, NCT02912793, NCT03893071 and NCT04860960). Company plans early phase clinical trial using Trappsol® Intravenous Cyclo â„¢ in Alzheimer’s disease based on encouraging data from an expanded access program for late-onset Alzheimer’s disease (NCT03624842). Additional indications for the active substance in Trappsol® Cyclo â„¢ are in development. For more information, visit the Company’s website:

Safe Harbor Declaration

This press release contains “forward-looking statements” regarding the Company’s current expectations regarding future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of the closing conditions relating to the Company. offer and the intended use of the proceeds of the offer. Statements that are not historical facts, such as “anticipates”, “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed or implied in such statements. Factors likely to influence the future performance of the company include the ability of the company to raise additional capital to develop its business as planned, the success of obtaining regulatory approval for clinical protocols, the recruitment of sufficient numbers of patients in clinical trials, unforeseen difficulties in demonstrating efficacy of biopharmaceuticals, success in attracting additional customers and profitable contracts, and regulatory risks associated with the production of pharmaceutical and food grade products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Form 10-K and 10-Q. Except as required by law, the company assumes no obligation to update or revise forward-looking statements as a result of new information or future events.

See the source version on


Jenene thomas
(833) 475-8247
[email protected]

Previous UBS clients raise $ 650 million for largest biotech impact fund
Next Cathie Wood's ARK leaves New York with a transfer to the Florida office